Top Players and Competitive Overview in the Artificial

Source Domain: www.openpr.com

The market for artificial intelligence (AI) clinical trial protocol feasibility tools is expected to grow significantly, with a forecasted market value of $2.76 billion by 2030, driven by factors such as quicker approval timelines and decentralized trial designs.
Key players in this market include IQVIA Holdings Inc., SAS Institute Inc., Veeva Systems Inc., Tempus AI Inc., Cytel Inc., and others, with Tempus AI’s acquisition of Deep 6 AI highlighted as a major development.
Emerging trends include advanced AI for protocol risk assessment, predictive recruitment models, enhanced integration of historical trial data, and cloud-based feasibility solutions.
Innovations like hybrid and barrier coating technologies are being developed to stabilize biological samples and ensure more accurate measurements of biomarkers, contributing to higher quality clinical trial data.
The market is segmented based on component (software and services), deployment mode (cloud-based and on-premises), application areas (protocol design, site selection, patient recruitment, etc.), and end-users including pharmaceutical companies, contract research organizations, academic and research institutes, and more.

You may have missed